DeutschNewstral
Article
jdsupra.com on 2015-06-30 20:15
Rejection of Gilead Patent Raises Issues for Companies Seeking Pharmaceutical Patent Protection in China
Related news
- Look before you leap: seeking to enforce your pharmaceutical patent may lead to unintended consequencesjdsupra.com
- [Event] Pharmaceutical Patent Term Extensions – The Only Specialized Forum on SPCs and Patent Protection in Europe and Around the World – June 25th-26th, Munich, Germanyjdsupra.com
- Patent Owners Win as Federal Circuit Reins in Gilead and AbbVie Double Patenting Rulingsjdsupra.com
America wants to waive patent protection for vaccinesThe Economist- Patent Infringement Safe Harbor and Importation Redefined: Ruling Incentivizes Generic Pharmaceutical Offshore Product Testingjdsupra.com
- Appealing the Rejection of a Patent Applicationjdsupra.com
- Design Patent Protection for Fashionjdsupra.com
- How to smoothly obtain a pharmaceutical patent in China?jdsupra.com
- Patent Settlement Update for Pharmaceutical Cases in Europejdsupra.com
- Complete Victory for Vifor Fresenius in Pharmaceutical Patent Litigationjdsupra.com
- News from Abroad: Eurasian Patent Office Launches Its Pharmaceutical Registerjdsupra.com
- Design Patent Protection For Replacement Partsjdsupra.com
- China Drug Administration Proposes Pharmaceutical Data Protection Guidelinesjdsupra.com
- Time to Consider Patent Protection in Chinajdsupra.com
AstraZeneca earnings fall amid patent protection lossesseattletimes.com- Patent Protection in the FoodTech Spacejdsupra.com
- Brazilian Supreme Court Ends Patent Term Extension and Retroactively Cuts Pharmaceutical and Medical Device Patent Termsjdsupra.com
- China: Patent Law Amendment brings sea change to pharmaceutical patent regimejdsupra.com